Literature DB >> 2985183

Cerebrospinal fluid levels of angiotensin-converting enzyme in Alzheimer's disease, Parkinson's disease and progressive supranuclear palsy.

G S Zubenko, L Volicer, L K Direnfeld, M Freeman, P J Langlais, R A Nixon.   

Abstract

Angiotensin-converting enzyme (ACE, E.C. 3.4.15.1) has been identified as a normal constituent of human cerebrospinal fluid (CSF). ACE activity in CSF from adult subjects without known neurologic disorder correlated positively (P = 0.002) with age between 50 and 90 years. Patients with moderate degrees of senile dementia of the Alzheimer's type and comparably demented patients with Parkinson's disease or progressive supranuclear palsy exhibited mean levels of ACE activity that were decreased 41, 27 and 53% respectively, compared to the mean level in an age and sex-matched group of neurologically intact individuals. These results raise the possibility that ACE activity in CSF may be an index of neuronal dysfunction in certain central neurodegenerative disorders.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2985183     DOI: 10.1016/0006-8993(85)91032-7

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  14 in total

1.  The angiotensin-converting enzyme gene as a possible risk or protective factor in Alzheimer's disease.

Authors:  T V Shcherbatykh; S A Kiryanov; G I Korovaitseva; N D Selezneva; N I Voskresenskaya; V E Golimbet; L Farrer; S I Gavrilova; E I Rogaev
Journal:  Neurosci Behav Physiol       Date:  2001 Mar-Apr

2.  Pig kidney angiotensin converting enzyme. Purification and characterization of amphipathic and hydrophilic forms of the enzyme establishes C-terminal anchorage to the plasma membrane.

Authors:  N M Hooper; J Keen; D J Pappin; A J Turner
Journal:  Biochem J       Date:  1987-10-01       Impact factor: 3.857

3.  ACE variants and association with brain Aβ levels in Alzheimer's disease.

Authors:  J Scott Miners; Zoë van Helmond; Merryn Raiker; Seth Love; Patrick G Kehoe
Journal:  Am J Transl Res       Date:  2010-10-15       Impact factor: 4.060

4.  Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes.

Authors:  Scott Miners; Emma Ashby; Shabnam Baig; Rachel Harrison; Hannah Tayler; Elizabeth Speedy; Jonathan A Prince; Seth Love; Patrick G Kehoe
Journal:  Am J Transl Res       Date:  2009-01-18       Impact factor: 4.060

Review 5.  The Role of the Renin-Angiotensin System in Amyloid Metabolism of Alzheimer's Disease.

Authors:  Chao-Liang Chou; Hung-I Yeh
Journal:  Acta Cardiol Sin       Date:  2014-03       Impact factor: 2.672

6.  Angiotensin-converting enzyme converts amyloid beta-protein 1-42 (Abeta(1-42)) to Abeta(1-40), and its inhibition enhances brain Abeta deposition.

Authors:  Kun Zou; Haruyasu Yamaguchi; Hiroyasu Akatsu; Takaaki Sakamoto; Mihee Ko; Kazushige Mizoguchi; Jian-Sheng Gong; Wenxin Yu; Takayuki Yamamoto; Kenji Kosaka; Katsuhiko Yanagisawa; Makoto Michikawa
Journal:  J Neurosci       Date:  2007-08-08       Impact factor: 6.167

Review 7.  Environmental estrogen-like chemicals and hydroxyl radicals induced by MPTP in the striatum: a review.

Authors:  Toshia Obata
Journal:  Neurochem Res       Date:  2002-05       Impact factor: 3.996

8.  Role of vitamin d in Parkinson's disease.

Authors:  Khanh L Ng; Lan Nguyễn
Journal:  ISRN Neurol       Date:  2012-03-07

Review 9.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505

10.  Angiotensins and Alzheimer's disease: a bench to bedside overview.

Authors:  Patrick G Kehoe
Journal:  Alzheimers Res Ther       Date:  2009-07-09       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.